What's in Cambium Bio Limited's pipeline?

Cambium Bio Limited has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Cambium Bio Limited's portfolio?

Top competitors by shared drug class: BioMarin Pharmaceutical.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cambium-bio-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Cambium Bio Limited — Portfolio Competitive Intelligence Brief

Cambium Bio Limited pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
CAM-101	CAM-101	phase 3	Gene therapy (AAV-based)	CDKN1C gene / p57 protein	Rare genetic disorders / Oncology

Therapeutic area mix

Rare genetic disorders / Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

BioMarin Pharmaceutical · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cambium Bio Limited:

Cite this brief

Drug Landscape (2026). Cambium Bio Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cambium-bio-limited. Accessed 2026-05-16.